Rocket Pharmaceuticals clinical trials we track

Check company identity source

Phase 2 4 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Evaluation of efficacy via primary endpoint comprised of LAMP2 myocardial tissue expression and left ventricular mass index Description: Increase of myocardial tissue expression of LAMP2 protein and decrease in left ventricular mass index (LVMI). Time frame: 12 Months post-infusion. After: Measure: Evaluation of Efficacy: Improvement as assessed via primary endpoint comprised of LAMP2 myocardial tissue expression and left ventricular mass index (LVMI) Description: Myocardial tissue expression of LAMP2 protein improved from baseline to ≥ Grade 1 (by IHC), AND, ≥ 10% decrease in LVMI from baseline. Time frame: 12 months post-infusion.

Planned enrollment increased by 4 participants

Before: 14 participants (planned). After: 18 participants (planned).

Primary completion date changed

Before: Apr 2028. After: Jun 2028.

Check registry source